Abstract
In this study, a nonlinear quantitative structure-activity relationship model for the prediction of the IC50 of trisubstituted thiazoles as Cdc7 kinase inhibitors was developed by the gene expression programming (GEP). This model is based on five descriptors which were selected from the descriptors’ pool by heuristic method (HM). GEP rendered a good correlation between the experimental and predicted log (IC50) values with a correlation coefficient and a mean error of 0.85 and 0.22 for the training set, 0.84 and 0.39 for the testing set, respectively. The results indicate that this QSAR model has good predictive capability and it points to further optimization opportunities for Cdc7 kinase inhibitors.
Keywords: Gene expression programming, IC50, kinase inhibitors, quantitative structure activity relationship, cell division cycle 7, trisubstituted thiazoles.
Letters in Drug Design & Discovery
Title:Studies on the IC50 of Trisubstituted Thiazoles as Cdc7 Kinase Inhibitors
Volume: 13 Issue: 1
Author(s): Huazhen Yang, Xun Liu, Zhiling Ye, Fucheng Song, Lianhua Cui, Zhuang Yu, Hongzong Si and Honglin Zhai
Affiliation:
Keywords: Gene expression programming, IC50, kinase inhibitors, quantitative structure activity relationship, cell division cycle 7, trisubstituted thiazoles.
Abstract: In this study, a nonlinear quantitative structure-activity relationship model for the prediction of the IC50 of trisubstituted thiazoles as Cdc7 kinase inhibitors was developed by the gene expression programming (GEP). This model is based on five descriptors which were selected from the descriptors’ pool by heuristic method (HM). GEP rendered a good correlation between the experimental and predicted log (IC50) values with a correlation coefficient and a mean error of 0.85 and 0.22 for the training set, 0.84 and 0.39 for the testing set, respectively. The results indicate that this QSAR model has good predictive capability and it points to further optimization opportunities for Cdc7 kinase inhibitors.
Export Options
About this article
Cite this article as:
Yang Huazhen, Liu Xun, Ye Zhiling, Song Fucheng, Cui Lianhua, Yu Zhuang, Si Hongzong and Zhai Honglin, Studies on the IC50 of Trisubstituted Thiazoles as Cdc7 Kinase Inhibitors, Letters in Drug Design & Discovery 2016; 13 (1) . https://dx.doi.org/10.2174/1570180812999150713144215
DOI https://dx.doi.org/10.2174/1570180812999150713144215 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of YY1 in Oncogenesis and Its Potential as a Drug Target in Cancer Therapies
Current Cancer Drug Targets Iron and Iron Chelators: A Review on Potential Effects on Skin Aging
Current Aging Science Patent Selections :
Recent Patents on Biomarkers Enteral Administration of TKIs: Report of a Response to Ceritinib in an ALK-positive NSCLC Patient and Literature Review
Current Drug Targets Recent Advances in Combined Modality Therapy for Locally Advanced Head and Neck Cancer
Current Cancer Drug Targets Power from the Garden: Plant Compounds as Inhibitors of the Hallmarks of Cancer
Current Medicinal Chemistry CDKN2B-AS1: An Indispensable Long Non-coding RNA in Multiple Diseases
Current Pharmaceutical Design Targeted Therapy for Advanced Renal Cell Cancer: Cytokines and Beyond
Current Pharmaceutical Design Quadruplex DNA: A Promising Drug Target for the Medicinal Inorganic Chemist
Current Topics in Medicinal Chemistry Lung Cancer Chemotherapy, New Treatment and Related Patents
Recent Patents on Anti-Cancer Drug Discovery Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design Estrogen-Induced Genetic Alterations and Their Role in Carcinogenicity
Current Genomics Statins and Type 2 Diabetes Mellitus: An Update After 1 Year
Current Pharmaceutical Design Nitric Oxide in Health and Disease from the Point of View of the Otorhinolaryngologist
Current Pharmaceutical Design Viral Vectors for Gene-Directed Enzyme Prodrug Therapy
Current Gene Therapy Pathology of the HPV-associated Oropharyngeal Carcinoma
Current Cancer Therapy Reviews PI3K/Akt/JNK/c-Jun Signaling Pathway is a Mediator for Arsenite- Induced Cyclin D1 Expression and Cell Growth in Human Bronchial Epithelial Cells
Current Cancer Drug Targets Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk
Current Cancer Therapy Reviews Epithelial-Mesenchymal Plasticity of Breast Cancer Stem Cells: Implications for Metastasis and Therapeutic Resistance
Current Pharmaceutical Design Antitumor Activities of Interleukin-27 on Melanoma
Endocrine, Metabolic & Immune Disorders - Drug Targets